NCT00566410View on ClinicalTrials.gov

A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Neoplasms
Interventions
DRUG

Dichloroacetate

Continuous daily oral dosage (bid).

Trial Locations (1)

T6G 1Z2

Cross Cancer Institute, Edmonton

All Listed Sponsors
collaborator

Cross Cancer Institute

OTHER

lead

AHS Cancer Control Alberta

OTHER

NCT00566410 - A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours | Biotech Hunter | Biotech Hunter